Durlobactam/Sulbactam sodium

Tier C — Watch / trade

Entasis Therapeutics Inc

Originator

2023

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：TEM, Beta Lactamase

Brand：Xacduro, XACDURO

Indications (approved)：不动杆菌感染, Ventilator-associated pneumonia, Bacterial pneumonia, Hospital-acquired pneumonia

Regional status

Approved

2023-05-23

No progress

2019-09-05

China

Approved

2024-05-15

Japan

Factories producing this API9

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

9 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Durlobactam/Sulbactam sodium?

Approved indications include: 不动杆菌感染, Ventilator-associated pneumonia, Bacterial pneumonia, Hospital-acquired pneumonia.

When does the Durlobactam/Sulbactam sodium patent expire?

No public expiry year is available for Durlobactam/Sulbactam sodium yet; this page updates once verified.

How do I get a quote for Durlobactam/Sulbactam sodium intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27